# A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

> **NCT02207725** · PHASE3 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 68 (actual)

## Conditions studied

- Bleeding

## Interventions

- **BIOLOGICAL:** Andexanet
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02207725
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-09
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207725, "A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02207725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*